At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 71 enrolled
Drug / intervention
Ruxolitinib Phosphate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-Cell and Peripheral T-Cell Non-Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Ruxolitinib Phosphate for Recurrent Diffuse Large B-Cell Lymphoma and 3 related conditions. Completed, enrolled 71 participants across 3 sites.
Detailed Summary
This phase II trial studies how well ruxolitinib phosphate works in treating patients with diffuse large B-cell or peripheral T-cell non-Hodgkin lymphoma that has returned (relapsed) or that does not respond to treatment (refractory) after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Diffuse Large B-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedSep 2011
Primary CompletionOct 2020
Study CompletionMay 2021
TodayJul 2026
First PostedSep 9, 2011
Enrollment StartAug 12, 2011
Primary CompletionOct 28, 2020
Study CompletionMay 26, 2021
TodayJul 2, 2026
Enrollment to primary: 9.2 yearsPosted 14.8 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Ruxolitinib Phosphatedrug
Given PO